ACADIA PHARMACEUTICALS INC. Research and Development Expense
ACADIA PHARMACEUTICALS INC. (ACAD) reported Research and Development Expense of $81.56 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- ACADIA PHARMACEUTICALS INC. research and development expense for the quarter ending 2026-06-30 was $81.56M, a 4.62% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. research and development expense for the quarter ending 2026-03-31 was $76.87M, a 1.78% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. research and development expense for the quarter ending 2025-12-31 was $84.76M, a 15.86% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. research and development expense for the quarter ending 2025-09-30 was $87.83M, a 31.86% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. research and development expense for fiscal 2025 was $328.80M, a 8.43% increase from fiscal 2024.
- ACADIA PHARMACEUTICALS INC. research and development expense for fiscal 2024 was $303.25M, a 13.76% decline from fiscal 2023.
- ACADIA PHARMACEUTICALS INC. research and development expense for fiscal 2023 was $351.62M, a 2.75% decline from fiscal 2022.
- ACADIA PHARMACEUTICALS INC. research and development expense for fiscal 2022 was $361.57M, a 51.02% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $81.56M 10-Q · filed 2026-08-05 | $158.42M 10-Q · filed 2026-08-05 | $243.18M derived: sum of 3 quarters · filed 2026-08-05 | $331.01M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $76.87M 10-Q · filed 2026-05-07 | $161.63M derived: sum of 2 quarters · filed 2026-05-07 | $249.45M derived: sum of 3 quarters · filed 2026-05-07 | $327.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $84.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $172.59M derived: sum of 2 quarters · filed 2026-02-26 | $250.54M derived: sum of 3 quarters · filed 2026-08-05 | $328.80M 10-K · filed 2026-02-26 |
| 2025-09-30 | $87.83M 10-Q · filed 2025-11-06 | $165.78M derived: sum of 2 quarters · filed 2026-08-05 | $244.04M 10-Q · filed 2025-11-06 | $344.78M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $77.95M 10-Q · filed 2026-08-05 | $156.22M 10-Q · filed 2026-08-05 | $256.95M derived: sum of 3 quarters · filed 2026-08-05 | $323.55M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $78.27M 10-Q · filed 2026-05-07 | $179.00M derived: sum of 2 quarters · filed 2026-05-07 | $245.60M derived: sum of 3 quarters · filed 2026-05-07 | $321.83M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $100.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $167.34M derived: sum of 2 quarters · filed 2026-02-26 | $243.57M derived: sum of 3 quarters · filed 2026-02-26 | $303.25M 10-K · filed 2026-02-26 |
| 2024-09-30 | $66.61M 10-Q · filed 2025-11-06 | $142.84M derived: sum of 2 quarters · filed 2025-11-06 | $202.52M 10-Q · filed 2025-11-06 | $269.26M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $76.23M 10-Q · filed 2025-08-07 | $135.91M 10-Q · filed 2025-08-07 | $202.65M derived: sum of 3 quarters · filed 2026-02-26 | $359.62M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $59.68M 10-Q · filed 2025-05-08 | $126.42M derived: sum of 2 quarters · filed 2026-02-26 | $283.38M derived: sum of 3 quarters · filed 2026-02-26 | $342.15M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $66.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $223.70M derived: sum of 2 quarters · filed 2026-02-26 | $282.48M derived: sum of 3 quarters · filed 2026-02-26 | $351.62M 10-K · filed 2026-02-26 |
| 2023-09-30 | $156.96M 10-Q · filed 2024-11-07 | $215.73M derived: sum of 2 quarters · filed 2024-11-07 | $284.88M 10-Q · filed 2024-11-07 | $360.62M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $58.77M 10-Q · filed 2024-08-07 | $127.92M 10-Q · filed 2024-08-07 | $203.65M derived: sum of 3 quarters · filed 2025-02-27 | $284.99M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $69.14M 10-Q · filed 2024-05-09 | $144.88M derived: sum of 2 quarters · filed 2025-02-27 | $226.22M derived: sum of 3 quarters · filed 2025-02-27 | $301.86M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $75.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $157.07M derived: sum of 2 quarters · filed 2025-02-27 | $232.72M derived: sum of 3 quarters · filed 2025-02-27 | $361.57M 10-K · filed 2025-02-27 |
| 2022-09-30 | $81.34M 10-Q · filed 2023-11-03 | $156.98M derived: sum of 2 quarters · filed 2023-11-03 | $285.84M 10-Q · filed 2023-11-03 | $352.78M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $75.65M 10-Q · filed 2023-08-03 | $204.50M 10-Q · filed 2023-08-03 | $271.44M derived: sum of 3 quarters · filed 2024-02-28 | $330.01M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $128.85M 10-Q · filed 2023-05-08 | $195.80M derived: sum of 2 quarters · filed 2024-02-28 | $254.36M derived: sum of 3 quarters · filed 2024-02-28 | $311.30M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $66.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $125.51M derived: sum of 2 quarters · filed 2024-02-28 | $182.44M derived: sum of 3 quarters · filed 2024-02-28 | $239.41M 10-K · filed 2024-02-28 |
| 2021-09-30 | $58.56M 10-Q · filed 2022-11-03 | $115.50M derived: sum of 2 quarters · filed 2022-11-03 | $172.47M 10-Q · filed 2022-11-03 | $234.59M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $56.94M 10-Q · filed 2022-08-09 | $113.91M 10-Q · filed 2022-08-09 | $176.02M derived: sum of 3 quarters · filed 2023-02-28 | $296.11M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $56.97M 10-Q · filed 2022-05-05 | $119.09M derived: sum of 2 quarters · filed 2023-02-28 | $239.17M derived: sum of 3 quarters · filed 2023-02-28 | $303.47M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $62.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $182.20M derived: sum of 2 quarters · filed 2023-02-28 | $246.49M derived: sum of 3 quarters · filed 2023-02-28 | $319.13M 10-K · filed 2023-02-28 |
| 2020-09-30 | $120.08M 10-Q · filed 2021-11-09 | $184.38M derived: sum of 2 quarters · filed 2021-11-09 | $257.01M 10-Q · filed 2021-11-09 | $314.53M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $64.30M 10-Q · filed 2021-08-05 | $136.93M 10-Q · filed 2021-08-05 | $194.45M derived: sum of 3 quarters · filed 2022-03-01 | $257.07M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $72.64M 10-Q · filed 2021-05-06 | $130.16M derived: sum of 2 quarters · filed 2022-03-01 | $192.78M derived: sum of 3 quarters · filed 2022-03-01 | $260.10M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $57.52M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $120.14M derived: sum of 2 quarters · filed 2022-03-01 | $187.46M derived: sum of 3 quarters · filed 2022-03-01 | $240.38M 10-K · filed 2022-03-01 |
| 2019-09-30 | $62.62M 10-Q · filed 2020-11-04 | $129.94M derived: sum of 2 quarters · filed 2020-11-04 | $182.87M 10-Q · filed 2020-11-04 | $231.05M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $67.32M 10-Q · filed 2020-08-06 | $120.24M 10-Q · filed 2020-08-06 | $168.43M derived: sum of 3 quarters · filed 2021-02-25 | $221.54M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $52.92M 10-Q · filed 2020-05-08 | $101.11M derived: sum of 2 quarters · filed 2021-02-25 | $154.22M derived: sum of 3 quarters · filed 2021-02-25 | $200.81M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $48.18M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $101.30M derived: sum of 2 quarters · filed 2021-02-25 | $147.89M derived: sum of 3 quarters · filed 2021-02-25 | $187.16M 10-K · filed 2021-02-25 |
| 2018-09-30 | $53.11M 10-Q · filed 2019-10-31 | $99.70M derived: sum of 2 quarters · filed 2019-10-31 | $138.98M 10-Q · filed 2019-10-31 | $182.16M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $46.59M 10-Q · filed 2019-08-01 | $85.87M 10-Q · filed 2019-08-01 | $129.05M derived: sum of 3 quarters · filed 2020-02-27 | $165.47M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $39.28M 10-Q · filed 2019-05-02 | $82.45M derived: sum of 2 quarters · filed 2020-02-27 | $118.88M derived: sum of 3 quarters · filed 2020-02-27 | $153.06M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $43.18M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $79.60M derived: sum of 2 quarters · filed 2020-02-27 | $113.78M derived: sum of 3 quarters · filed 2020-02-27 | $149.19M 10-K · filed 2020-02-27 |
| 2017-09-30 | $36.42M 10-Q · filed 2018-11-06 | $70.60M derived: sum of 2 quarters · filed 2018-11-06 | $106.01M 10-Q · filed 2018-11-06 | $136.23M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $34.18M 10-Q · filed 2018-08-08 | $69.59M 10-Q · filed 2018-08-08 | $99.81M derived: sum of 3 quarters · filed 2019-02-27 | $125.62M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $35.41M 10-Q · filed 2018-05-04 | $65.63M derived: sum of 2 quarters · filed 2019-02-27 | $91.44M derived: sum of 3 quarters · filed 2019-02-27 | $111.92M derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | $30.22M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $56.03M derived: sum of 2 quarters · filed 2019-02-27 | $76.51M derived: sum of 3 quarters · filed 2019-02-27 | $99.28M 10-K · filed 2019-02-27 |
| 2016-09-30 | $25.81M 10-Q · filed 2017-11-07 | $46.29M derived: sum of 2 quarters · filed 2017-11-07 | $69.07M 10-Q · filed 2017-11-07 | $89.53M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $20.48M 10-Q · filed 2017-08-08 | $43.25M 10-Q · filed 2017-08-08 | $63.72M derived: sum of 3 quarters · filed 2018-02-27 | $82.45M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $22.77M 10-Q · filed 2017-05-09 | $43.24M derived: sum of 2 quarters · filed 2018-02-27 | $61.97M derived: sum of 3 quarters · filed 2018-02-27 | $80.35M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | $20.47M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $39.20M derived: sum of 2 quarters · filed 2018-02-27 | $57.57M derived: sum of 3 quarters · filed 2018-02-27 | $73.87M 10-K · filed 2018-02-27 |
| 2015-09-30 | $18.73M 10-Q · filed 2016-11-07 | $37.11M derived: sum of 2 quarters · filed 2016-11-07 | $53.40M 10-Q · filed 2016-11-07 | $71.58M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-06-30 | $18.38M 10-Q · filed 2016-08-04 | $34.67M 10-Q · filed 2016-08-04 | $52.86M derived: sum of 3 quarters · filed 2017-02-28 | $69.81M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-03-31 | $16.30M 10-Q · filed 2016-05-05 | $34.48M derived: sum of 2 quarters · filed 2017-02-28 | $51.43M derived: sum of 3 quarters · filed 2017-02-28 | $65.23M derived: sum of 4 quarters · filed 2017-02-28 |
| 2014-12-31 | $18.18M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $35.13M derived: sum of 2 quarters · filed 2017-02-28 | $48.93M derived: sum of 3 quarters · filed 2017-02-28 | $60.60M 10-K · filed 2017-02-28 |
| 2014-09-30 | $16.95M 10-Q · filed 2015-11-05 | $30.75M derived: sum of 2 quarters · filed 2015-11-05 | $42.42M 10-Q · filed 2015-11-05 | $50.34M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $13.80M 10-Q · filed 2015-08-06 | $25.47M 10-Q · filed 2015-08-06 | $33.39M derived: sum of 3 quarters · filed 2016-02-29 | $40.65M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $11.67M 10-Q · filed 2015-05-07 | $19.59M derived: sum of 2 quarters · filed 2016-02-29 | $26.85M derived: sum of 3 quarters · filed 2016-02-29 | $33.96M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $7.92M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $15.18M derived: sum of 2 quarters · filed 2016-02-29 | $22.29M derived: sum of 3 quarters · filed 2016-02-29 | $26.72M 10-K · filed 2016-02-29 |
| 2013-09-30 | $7.25M 10-Q · filed 2014-11-10 | $14.37M derived: sum of 2 quarters · filed 2014-11-10 | $18.80M 10-Q · filed 2014-11-10 | $23.70M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-06-30 | $7.11M 10-Q · filed 2014-08-05 | $11.54M 10-Q · filed 2014-08-05 | $16.44M derived: sum of 3 quarters · filed 2015-02-26 | $20.84M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-03-31 | $4.43M 10-Q · filed 2014-05-06 | $9.33M derived: sum of 2 quarters · filed 2015-02-26 | $13.73M derived: sum of 3 quarters · filed 2015-02-26 | $18.20M derived: sum of 4 quarters · filed 2015-02-26 |
| 2012-12-31 | $4.90M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $9.30M derived: sum of 2 quarters · filed 2015-02-26 | $13.77M derived: sum of 3 quarters · filed 2015-02-26 | $18.79M 10-K · filed 2015-02-26 |
| 2012-09-30 | $4.40M 10-Q · filed 2013-11-06 | $8.87M derived: sum of 2 quarters · filed 2013-11-06 | $13.89M 10-Q · filed 2013-11-06 | $18.32M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $4.47M 10-Q · filed 2013-08-06 | $9.49M 10-Q · filed 2013-08-06 | $13.92M derived: sum of 3 quarters · filed 2014-02-27 | $18.07M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $5.02M 10-Q · filed 2013-05-07 | $9.45M derived: sum of 2 quarters · filed 2014-02-27 | $13.60M derived: sum of 3 quarters · filed 2014-02-27 | $17.92M derived: sum of 4 quarters · filed 2014-02-27 |
| 2011-12-31 | $4.42M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $8.58M derived: sum of 2 quarters · filed 2014-02-27 | $12.90M derived: sum of 3 quarters · filed 2014-02-27 | $17.31M 10-K · filed 2014-02-27 |
| 2011-09-30 | $4.16M 10-Q · filed 2012-11-05 | $8.47M derived: sum of 2 quarters · filed 2012-11-05 | $12.88M 10-Q · filed 2012-11-05 | $17.64M derived: sum of 4 quarters · filed 2013-03-12 |
| 2011-06-30 | $4.32M 10-Q · filed 2012-08-08 | $8.73M 10-Q · filed 2012-08-08 | $13.48M derived: sum of 3 quarters · filed 2013-03-12 | $18.45M derived: sum of 4 quarters · filed 2013-03-12 |
| 2011-03-31 | $4.41M 10-Q · filed 2012-05-08 | $9.17M derived: sum of 2 quarters · filed 2013-03-12 | $14.13M derived: sum of 3 quarters · filed 2013-03-12 | $19.18M derived: sum of 4 quarters · filed 2013-03-12 |
| 2010-12-31 | $4.76M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | $9.72M derived: sum of 2 quarters · filed 2013-03-12 | $14.76M derived: sum of 3 quarters · filed 2013-03-12 | $20.58M 10-K · filed 2013-03-12 |
| 2010-09-30 | $4.96M 10-Q · filed 2011-11-09 | $10.01M derived: sum of 2 quarters · filed 2011-11-09 | $15.82M 10-Q · filed 2011-11-09 | |
| 2010-06-30 | $5.04M 10-Q · filed 2011-08-10 | $10.86M 10-Q · filed 2011-08-10 | ||
| 2009-12-31 | $41.59M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |